It is estimated that between 5,000 and 8,000 known rare diseases that affects about 250 million people around the world. As a leader in orphan disease area for over twenty years, Shire has focused on research, development and commercialization of therapies for Fabry’s disease, hereditary angioedema (HAE) Hunter syndrome and Gaucher disease, as well as building and invest in a pipeline of innovative products and solutions for the treatment of rare diseases.“For many patients and their families, the journey to diagnosis and subsequent treatment for a rare disease can be a long and complicated process,” said Sylvie Gregoire Gr, President of Shire HGT. “Shire is committed to providing the people change the conditions of life for a better life – and for us, which includes improving access to information and provide the necessary care for rare diseases, we are proud to support World Day of the rare disease and hope. is not that day can highlight the great people that include the rare disease community, and their unique and important position as a global public health problem. ”
In Switzerland, Shire will provide support to sponsor the first “STOP RARE ‘awareness of the disease in Lausanne, and the Symposium” Wissen Heilt “held in Basel on February 26.
As part of its external action, Shire genes also supports global project “that you wear CareTM” campaign, an effort to use the basic jeans to increase global awareness of rare genetic diseases. The company expects to distribute over 5000 employees denim blue ribbons in various locations around the world of business.
In conjunction with the Day of rare diseases in the world 2011, Shire is extending and upgrading BraveCommunity.com, its online resource center that aims to connect patients with each other and provide important information on rare diseases. First launched in the U.S. in early 2009, the site is now available for the British public, with other countries, sites dedicated to follow. Please visit here to register at the request of information on rare genetic diseases.